Hospital-Acquired Infections: A Danger Hidden in Plain Sight and Antimicrobial Coating as Supplemental Residual Protection
By DaXem GmbH | virexbuster.de | Published: 21 May 2026 Quick answer: Nosocomial (hospital-acquired) infections affect approximately 3.8 million EU patients every year. A major contributing factor is the gap between disinfection events: surfaces are re-contaminated within minutes of cleaning. VireXbuster is a Supplemental Residual Antimicrobial Product (EPA classification) that provides continuous broad-spectrum antimicrobial activity on treated surfaces — walls, bed rails, medical equipment housings, HVAC systems — between every cleaning cycle, 24 hours a Read more











